SCHEMBL4073435

SCHEMBL4073435

COc1ccnc(Cl)c1C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DOT1L Q8TEK3 1/20 0.39
DYRK1A Q13627 2/20 0.39
MAPK1 P28482 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
MAPT P10636 1/20 0.37
KMT2A Q03164 1/20 0.37
ALDH1A1 P00352 5/20 0.36
GAA P10253 1/20 0.36
PKM P14618 1/20 0.36
RAB9A P51151 1/20 0.36
LMNA P02545 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
HSD17B10 Q99714 1/20 0.36
BRD4 O60885 2/20 0.35
NFE2L2 Q16236 1/20 0.35
KDM4E B2RXH2 1/20 0.35
HPGD P15428 1/20 0.35
POLB P06746 1/20 0.35
BRD2 P25440 1/20 0.35
BRD3 Q15059 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30320423 0.80 DYRK1A (0.40) DOT1LDYRK1AMAPK1L3MBTL1MAPT
SCHEMBL1662248 0.80 DYRK1A (0.40) DOT1LDYRK1AMAPK1L3MBTL1MAPT
SCHEMBL1445758 0.78 PKM (0.40) DOT1LDYRK1AMAPK1L3MBTL1MAPT
SCHEMBL30397417 0.78 PKM (0.40) DOT1LDYRK1AMAPK1L3MBTL1MAPT
SCHEMBL4080571 0.77 MAOA (0.42) ALDH1A1GAACCR1CCR5CCR8
SCHEMBL31278202 0.77 MAOA (0.42) ALDH1A1GAACCR1CCR5CCR8
SCHEMBL24122438 0.77 MAPT (0.44) DYRK1AMAPK1L3MBTL1MAPTKMT2A
Hydrochloric Acid SCHEMBL3994769 0.77 PKM (0.42) DOT1LDYRK1AMAPK1L3MBTL1MAPT
SCHEMBL16198185 0.77 HPGD (0.40) DOT1LDYRK1AMAPK1L3MBTL1MAPT
SCHEMBL1760983 0.77 DYRK1A (0.45) DYRK1AMAPK1L3MBTL1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125364-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER (US) 2026-05-07 US disclosed
US-20240317713-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER (US) 2024-09-26 US disclosed
US-11964961-B2 Heteroaromatic compounds and their use as dopamine D1 ligands PFIZER INC. (US) 2024-04-23 US disclosed
EP-3421462-B1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER (US) 2023-04-05 EP disclosed
US-20210300899-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER (US) 2021-09-30 US disclosed
US-11014909-B2 Heteroaromatic compounds and their use as dopamine D1 ligands PFIZER INC. (US) 2021-05-25 US disclosed
US-20200283407-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER (US) 2020-09-10 US disclosed
US-10696658-B2 Heteroaromatic compounds and their use as dopamine D1 ligands PFIZER INC. (US) 2020-06-30 US disclosed
US-10421744-B2 Heteroaromatic compounds and their use as dopamine D1 ligands PFIZER INC. (US) 2019-09-24 US disclosed
EP-3013813-B1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER (US) 2019-04-03 EP disclosed
US-7572918-B2 Prepared in high yield and high purity without the need for isolation of intermediates and chromatographic purification; useful as muscarinic receptor antagonists; 4-{N-[7-(3-(S)-1-carbamoyl-1,1-diphenylmethyl)-pyrrolidin-1-yl)-hept-1-yl]-N-(isopropyl)amino}-1-(4-methoxypyrid-3-ylmethyl)-piperidine THERAVANCE, INC. (US) 2009-08-11 US disclosed
US-20080091034-A1 Substituted 4-amino-1-(pyridylmethyl)piperidine and related compounds THERAVANCE, INC. 2008-04-17 US disclosed
US-7285564-B2 Substituted 4-amino-1-(pyridylmethyl)piperidine and related compounds THERAVANCE, INC. (US) 2007-10-23 US disclosed
EP-1556372-B1 SUBSTITUTED 4-AMINO-1-(PYRIDYLMETHYL) PIPERIDINE AS MUSCARINIC RECEPTOR ANTAGONISTS THERAVANCE INC (US) 2007-05-30 EP disclosed
US-20060094878-A1 Process for preparing substituted 4-amino-1-(pyridylmethyl)piperidine and related compounds THERAVANCE, INC. 2006-05-04 US disclosed
EP-0696281-B1 NOVEL 5-PYRROLYL-2-PYRIDYLMETHYLSULFINYL BENZIMIDAZOLE DERIVATIVES IL YANG PHARM CO LTD (KR) 1999-05-12 EP disclosed
US-5703097-A ANTIULCER AGENTS IL-YANG PHARM. CO., LTD. (KR) 1997-12-30 US disclosed
US-5554631-A ANTIULCER IL-YANG PHARM. CO., LTD. (KR) 1996-09-10 US disclosed
EP-0696281-A1 NOVEL 5-PYRROLYL-2-PYRIDYLMETHYLSULFINYL BENZIMIDAZOLE DERIVATIVES IL-YANG PHARM. CO., LTD. (KR) 1996-02-14 EP disclosed
WO-1995023140-A1 NOVEL 5-PYRROLYL-2-PYRIDYLMETHYLSULFINYL BENZIMIDAZOLE DERIVATIVES IL-YANG PHARM. CO., LTD. (KR) 1995-08-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125364-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS HTR6, HTR3C, OPRD1 DOT1L 3397/4885DYRK1A 2229/4885MAPK1 3257/4885
US-20060094878-A1 Process for preparing substituted 4-amino-1-(pyridylmethyl)piperidine and related compounds CHRM4, CHRM3, CHRM1 DOT1L 2230/4885DYRK1A 2309/4885MAPK1 1595/4885
US-11964961-B2 Heteroaromatic compounds and their use as dopamine D1 ligands DRD2, DRD1, HTR1D DOT1L 3478/4885DYRK1A 1717/4885MAPK1 2934/4885
US-10421744-B2 Heteroaromatic compounds and their use as dopamine D1 ligands DRD1, SNCA, DRD2 DOT1L 2592/4885DYRK1A 597/4885MAPK1 695/4885
US-20080091034-A1 Substituted 4-amino-1-(pyridylmethyl)piperidine and related compounds CHRM5, CHRM1, CHRM3 DOT1L 1884/4885DYRK1A 1473/4885MAPK1 1867/4885
US-20210300899-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS DRD2, DRD1, HTR1D DOT1L 3478/4885DYRK1A 1717/4885MAPK1 2934/4885
US-20240317713-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS DRD2, DRD1, HTR1D DOT1L 3478/4885DYRK1A 1717/4885MAPK1 2934/4885
US-20200283407-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS DRD2, DRD1, SNCA DOT1L 2134/4885DYRK1A 650/4885MAPK1 1223/4885
US-10696658-B2 Heteroaromatic compounds and their use as dopamine D1 ligands DRD1, SNCA, DRD2 DOT1L 2592/4885DYRK1A 597/4885MAPK1 695/4885
US-11014909-B2 Heteroaromatic compounds and their use as dopamine D1 ligands DRD2, DRD1, SNCA DOT1L 2134/4885DYRK1A 650/4885MAPK1 1223/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.